|
|
Volumn 355, Issue , 2016, Pages
|
|
Optimal dosing of rivaroxaban is undefined
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
APIXABAN;
DABIGATRAN;
RIVAROXABAN;
BLOOD CLOTTING FACTOR 10A INHIBITOR;
ANTICOAGULATION;
ATRIAL FIBRILLATION;
BLEEDING;
DRUG DOSE REGIMEN;
DRUG ELIMINATION;
DRUG HALF LIFE;
HUMAN;
LETTER;
PRIORITY JOURNAL;
COMPLICATION;
HALF LIFE TIME;
ATRIAL FIBRILLATION;
FACTOR XA INHIBITORS;
HALF-LIFE;
HUMANS;
RIVAROXABAN;
|
|
EID: 84992549256
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.i5549 Document Type: Letter |
|
Times cited : (11)
|
|
References (4)
|
